Modern Chinese Medicine Group Co. Ltd. (HK:1643)
:1643
Want to see HK:1643 full AI Analyst Report?
1643 Stock Chart & Stats
HK$0.51
<HK$0.01(1.54%)
At close: 4:00 PM EST
HK$0.51
<HK$0.01(1.54%)
Day’s Range― - ―
52-Week RangeHK$0.35 - HK$3.26
Previous CloseN/A
Volume456.00K
Average Volume (3M)639.13K
Market Cap
HK$993.60M
Enterprise ValueHK$626.74M
Total Cash (Recent Filing)HK$229.81M
Total Debt (Recent Filing)HK$69.03K
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding720,000,000
10 Day Avg. Volume382,100
30 Day Avg. Volume639,133
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.61
Price to Sales (P/S)2.14
P/FCF Ratio-18.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetThe company's extremely low debt and sizable equity provide durable financial flexibility and low solvency risk. This balance-sheet strength supports continued operations, funding of working capital or selective investments during downturns, cushioning operational recovery timelines.
Demonstrated Cash-generation CapacityDespite recent stress, the business has shown it can convert earnings to cash (strong 2022 cash generation and positive 2025 operating cash flow). That underlying cash-generation ability supports sustainability and gives management time to restore margins and revenue.
Proven Margin Performance HistoricallyHistorical periods of robust margins and profitability indicate the business model and product mix can deliver attractive unit economics. If demand or pricing normalizes, the company has structural capacity to restore profitability rather than requiring a fundamental business model redesign.
Bears Say
Revenue And Profitability DeteriorationA large revenue decline with margin compression and a swing to net loss reflects weakened demand, adverse mix, or pricing pressure. This reduces operating leverage, impairs earnings power, and suggests material execution or market-share challenges that could persist absent structural fixes.
Volatile Free Cash FlowNegative and volatile free cash flow limits the firm's ability to invest, service obligations, or return capital. Sustained FCF weakness increases refinancing or funding risk and forces trade-offs between growth, R&D, or working-capital needs during a recovery period.
Declining Return On EquityFalling and negative ROE signals the company is not currently monetizing its capital base efficiently. Persistently low capital efficiency can deter reinvestment, constrain strategic initiatives, and undermine long-term shareholder value unless operational performance and margins improve.
Modern Chinese Medicine Group Co. Ltd. News
1643 FAQ
What was Modern Chinese Medicine Group Co. Ltd.’s price range in the past 12 months?
Modern Chinese Medicine Group Co. Ltd. lowest stock price was HK$0.34 and its highest was HK$3.26 in the past 12 months.
What is Modern Chinese Medicine Group Co. Ltd.’s market cap?
Modern Chinese Medicine Group Co. Ltd.’s market cap is HK$993.60M.
When is Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date?
Modern Chinese Medicine Group Co. Ltd.’s upcoming earnings report date is Aug 20, 2026 which is in 64 days.
How were Modern Chinese Medicine Group Co. Ltd.’s earnings last quarter?
Modern Chinese Medicine Group Co. Ltd. released its earnings results on Mar 30, 2026. The company reported -HK$0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.027.
Is Modern Chinese Medicine Group Co. Ltd. overvalued?
According to Wall Street analysts Modern Chinese Medicine Group Co. Ltd.’s price is currently Overvalued.
Does Modern Chinese Medicine Group Co. Ltd. pay dividends?
Modern Chinese Medicine Group Co. Ltd. pays a Notavailable dividend of HK$0.017 which represents an annual dividend yield of N/A. See more information on Modern Chinese Medicine Group Co. Ltd. dividends here
What is Modern Chinese Medicine Group Co. Ltd.’s EPS estimate?
Modern Chinese Medicine Group Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modern Chinese Medicine Group Co. Ltd. have?
Modern Chinese Medicine Group Co. Ltd. has 720,000,000 shares outstanding.
What happened to Modern Chinese Medicine Group Co. Ltd.’s price movement after its last earnings report?
Modern Chinese Medicine Group Co. Ltd. reported an EPS of -HK$0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.013%.
Which hedge fund is a major shareholder of Modern Chinese Medicine Group Co. Ltd.?
Currently, no hedge funds are holding shares in HK:1643
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Modern Chinese Medicine Group Co. Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
94.59%
12-Months-Change
Fundamentals
Return on Equity
-2.70%
Trailing 12-Months
Asset Growth
5.26%
Trailing 12-Months
Company Description
Modern Chinese Medicine Group Co. Ltd.
As an investment holding company, Modern Chinese Medicine Group Co., Ltd. manufactures and distributes traditional Chinese pharmaceutical products, primarily targeting the middle-aged and elderly populations across the People's Republic of China. Its extensive product line provides treatments for a wide array of health issues, including qi deficiency, blood stasis, cardiovascular and cerebrovascular conditions, digestive and gastrointestinal ailments, gynecological problems, as well as disorders affecting the respiratory and nervous systems. Established in 1986, the enterprise maintains its principal offices in Chengde, China, and operates as a subsidiary of Modern Biotechnology Group Holdings Co., Ltd.
Technical Analysis
Tong Ren Tang Technologies Co
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―